{
    "nct_id": "NCT04227847",
    "official_title": "A Phase 1 Study of SEA-CD70 in Myeloid Malignancies",
    "inclusion_criteria": "Part A Inclusion Criteria\n\n* Participants with cytologically/histologically confirmed MDS (2016 World Health Organization (WHO) classification) with\n\n  * Measurable disease per WHO MDS with excess blasts criteria\n  * MDS that is relapsed or refractory and must not have other therapeutic options\n  * Treatment failure after prior hypomethylating agent (HMA) therapy for MDS\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\nPart B Inclusion Criteria\n\n* Participants with cytologically/histologically confirmed MDS (WHO classification) with:\n\n  * Measurable disease per WHO MDS with excess blasts (MDS-EB) criteria\n  * MDS that is relapsed or refractory and must not have other therapeutic options\n  * Treatment failure after prior HMA therapy for MDS\n* ECOG Performance Status of 0-2\n\nPart C Inclusion Criteria\n\n* Participants with relapsed or refractory AML (ICC 2022) (except for acute promyelocytic leukemia [APL]):\n\n  * Who have received either 2 or 3 previous regimens\n  * Who have received 1 previous regimen to treat active disease and have at least one of the following:\n\n    * Age > 60 and ≤75 years.\n    * Primary resistant AML or secondary AML\n    * First CR duration <6 months\n    * Adverse-risk per European Leukemia Network genetic risk stratification\n* Age 18-75 years\n* ECOG performance status of 0-2\n\nParts D and F Inclusion Criteria\n\n* Participants with diagnosis of MDS or MDS/AML (ICC 2022 criteria)\n* Disease which has relapsed, failed to respond after minimum of 6 cycles, or progressed following an HMA in the immediately preceding line of therapy.\n* Eligible for continued therapy with azacitidine\n* ECOG Performance Status 0-2\n\nParts D and E Inclusion Criteria\n\n* Participants with diagnosis of MDS or MDS/AML (ICC 2022 criteria), previously untreated.\n* Participants with higher-risk per IPSS-M MDS and MDS/AML\n* ECOG Performance Status 0-2\n\nPart G Inclusion Criteria\n\n* Participants with diagnosis of AML (ICC 2022 criteria), previously untreated and ineligible for standard induction chemotherapy.\n* Age ≥18 years.\n* ECOG Performance Status of 0-2.\n\nExclusion Criteria (All Parts)\n\n* Previous exposure to CD70-targeted agents\n* Prior allogeneic hematopoietic stem cell transplant, for any condition\n* Central nervous system leukemia\n* History of clinically significant sickle cell anemia, autoimmune hemolytic anemia, or idiopathic thrombocytopenic purpura\n* Parts D, F and G only: Prior oral HMA or oral HMA-combinations\n* Part G: conditions that preclude enteral route of administration; concomitant use of strong/moderate CYP3A inducers; history of myeloproliferative neoplasm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}